LON:AGY Allergy Therapeutics (AGY) Share Price, News & Analysis GBX 4.82 +0.07 (+1.47%) As of 10:35 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarnings About Allergy Therapeutics Stock (LON:AGY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Allergy Therapeutics alerts:Sign Up Key Stats Today's Range 4.50▼ 550-Day Range 4.70▼ 6.7452-Week Range 4.50▼ 12.10Volume79,453 shsAverage Volume362,871 shsMarket Capitalization£305.23 millionP/E RatioN/ADividend Yield8.33%Price TargetN/AConsensus RatingN/A Company Overview Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees. Read More Receive AGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGY Stock News HeadlinesAllergy Therapeutics PlcJune 25, 2026 | fool.comAllergy Therapeutics agrees new debt fundingFebruary 24, 2026 | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 24 at 1:00 AM | Decentralized Masters (Ad)GSK grabs RAPT for $2.2B in big bet on food allergy drugsJanuary 21, 2026 | msn.comGSK digs in on allergies with $2.2 billion Rapt Therapeutics buyoutJanuary 20, 2026 | msn.comAllergy Therapeutics reports 7% revenue growth in first halfJanuary 19, 2026 | in.investing.comAllergy Therapeutics plc (AGY.L) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comSMALL CAP IDEA: Allergy Therapeutics transformation has redefined its trajectoryDecember 23, 2024 | msn.comSee More Headlines AGY Stock Analysis - Frequently Asked Questions How have AGY shares performed this year? Allergy Therapeutics' stock was trading at GBX 11.20 on January 1st, 2026. Since then, AGY stock has decreased by 57.0% and is now trading at GBX 4.82. How were Allergy Therapeutics' earnings last quarter? Allergy Therapeutics plc (LON:AGY) posted its earnings results on Tuesday, March, 31st. The company reported ($0.38) EPS for the quarter. The firm earned $36.28 million during the quarter. Allergy Therapeutics had a positive trailing twelve-month return on equity of 409.00% and a negative net margin of 85.46%. How do I buy shares of Allergy Therapeutics? Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Allergy Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include Royalty Pharma (RPRX), genedrive (GDR), Intel (INTC), IQE (IQE), AstraZeneca (AZN) and Babcock International Group (BAB). Company Calendar Last Earnings3/31/2026Today9/24/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:AGY CIKN/A Webwww.allergytherapeutics.com Phone+44-1903-844700FaxN/AEmployees612Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-30.7Net Income-£52.59 million Net Margins-85.46% Pretax MarginN/A Return on Equity409.00% Return on Assets-34.76% Debt Debt-to-Equity Ratio629.58 Current Ratio1.13 Quick Ratio1.48 Sales & Book Value Annual Sales£57.29 million Price / Sales5.33 Cash FlowGBX 1.32 per share Price / Cash Flow3.66 Book ValueGBX 0.10 per share Price / Book48.84Miscellaneous Outstanding Shares6,332,530,000Free FloatN/AMarket Cap£305.23 million OptionableNot Optionable Beta0.84 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (LON:AGY) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGY Stock Alerts